91 related articles for article (PubMed ID: 1818953)
21. Imidazole based non-peptide angiotensin II receptor antagonists. Investigation of the effect of the orientation of the imidazole ring on biological activity.
Wahhab A; Smith JR; Ganter RC; Moore DM; Hondrelis J; Matsoukas J; Moore GJ
Arzneimittelforschung; 1993 Nov; 43(11):1157-68. PubMed ID: 8292058
[TBL] [Abstract][Full Text] [Related]
22. Angiotensin II receptors are exclusively of the AT1 subtype in cultured human vascular smooth muscle cells.
Schachter M; Betteridge LJ; Hughes AD; Patel MK
Biochem Soc Trans; 1995 Aug; 23(3):458S. PubMed ID: 8566350
[No Abstract] [Full Text] [Related]
23. Acute myocardial and vascular responses to specific angiotensin II antagonism in the spontaneously hypertensive rat.
Cody RJ; Binkley PF; Haas GJ; Brown DM
Am J Hypertens; 1995 May; 8(5 Pt 1):500-8. PubMed ID: 7662227
[TBL] [Abstract][Full Text] [Related]
24. Autoradiographic localization of subtypes of angiotensin II antagonist binding in the rat brain.
Gehlert DR; Gackenheimer SL; Schober DA
Neuroscience; 1991; 44(2):501-14. PubMed ID: 1944896
[TBL] [Abstract][Full Text] [Related]
25. Antihypertensive and renal-protective effects of losartan in streptozotocin diabetic rats.
Kohzuki M; Yasujima M; Kanazawa M; Yoshida K; Fu LP; Obara K; Saito T; Abe K
J Hypertens; 1995 Jan; 13(1):97-103. PubMed ID: 7759858
[TBL] [Abstract][Full Text] [Related]
26. DuP 532, an angiotensin II receptor antagonist: first administration and comparison with losartan.
Goldberg MR; Lo MW; Christ DD; Chiou R; Furtek CI; Amit O; Carides A; Biollaz J; Piguet V; Nussberger J; Brunner HR
Clin Pharmacol Ther; 1997 Jan; 61(1):59-69. PubMed ID: 9024174
[TBL] [Abstract][Full Text] [Related]
27. Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure.
Levy BI; Benessiano J; Henrion D; Caputo L; Heymes C; Duriez M; Poitevin P; Samuel JL
J Clin Invest; 1996 Jul; 98(2):418-25. PubMed ID: 8755652
[TBL] [Abstract][Full Text] [Related]
28. Subtype 2 of angiotensin II receptors controls pressure-natriuresis in rats.
Lo M; Liu KL; Lantelme P; Sassard J
J Clin Invest; 1995 Mar; 95(3):1394-7. PubMed ID: 7883985
[TBL] [Abstract][Full Text] [Related]
29. Effect of the angiotensin antagonist DuP 753 on the renal adaptation to sodium restriction in the rat.
Jover B; Dupont M; Nafrialdi E; Mimran A
J Hypertens Suppl; 1991 Dec; 9(6):S210-1. PubMed ID: 1818949
[No Abstract] [Full Text] [Related]
30. The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices.
Stearns RA; Miller RR; Doss GA; Chakravarty PK; Rosegay A; Gatto GJ; Chiu SH
Drug Metab Dispos; 1992; 20(2):281-7. PubMed ID: 1352222
[TBL] [Abstract][Full Text] [Related]
31. Angiotensin-II receptor subtypes in fetal tissue of the rat: autoradiography, guanine nucleotide sensitivity, and association with phosphoinositide hydrolysis.
Tsutsumi K; Strömberg C; Viswanathan M; Saavedra JM
Endocrinology; 1991 Aug; 129(2):1075-82. PubMed ID: 1649738
[TBL] [Abstract][Full Text] [Related]
32. Internalization of the rat AT1a and AT1b receptors: pharmacological and functional requirements.
Conchon S; Monnot C; Teutsch B; Corvol P; Clauser E
FEBS Lett; 1994 Aug; 349(3):365-70. PubMed ID: 8050598
[TBL] [Abstract][Full Text] [Related]
33. Differential structural requirements for specific binding of nonpeptide and peptide antagonists to the AT1 angiotensin receptor. Identification of amino acid residues that determine binding of the antihypertensive drug losartan.
Ji H; Leung M; Zhang Y; Catt KJ; Sandberg K
J Biol Chem; 1994 Jun; 269(24):16533-6. PubMed ID: 8206967
[TBL] [Abstract][Full Text] [Related]
34. Human plasma protein binding of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) and its pharmacologically active metabolite EXP3174.
Christ DD
J Clin Pharmacol; 1995 May; 35(5):515-20. PubMed ID: 7657853
[TBL] [Abstract][Full Text] [Related]
35. Binding of [3H]angiotensin II and [3H]DuP 753 (Losartan) to rat liver homogenates reveals multiple sites. Relationship to AT1a- and AT1b-type angiotensin receptors and novel nonangiotensin binding sites.
Widdowson PS; Renouard A; Vilaine JP
Peptides; 1993; 14(4):829-37. PubMed ID: 8234032
[TBL] [Abstract][Full Text] [Related]
36. Differential development of angiotensin II receptor subtypes in the rat brain.
Tsutsumi K; Saavedra JM
Endocrinology; 1991 Jan; 128(1):630-2. PubMed ID: 1986946
[TBL] [Abstract][Full Text] [Related]
37. Characterization and development of angiotensin II receptor subtypes (AT1 and AT2) in rat brain.
Tsutsumi K; Saavedra JM
Am J Physiol; 1991 Jul; 261(1 Pt 2):R209-16. PubMed ID: 1858948
[TBL] [Abstract][Full Text] [Related]
38. Further studies on the selectivity of DuP 753, a nonpeptide angiotensin II receptor antagonist.
Wong PC; Tam SW; Herblin WF; Timmermans PB
Eur J Pharmacol; 1991 Apr; 196(2):201-3. PubMed ID: 1651874
[No Abstract] [Full Text] [Related]
39. Nonpeptidic angiotensin II antagonists: synthesis and in vitro activity of a series of novel naphthalene and tetrahydronaphthalene derivatives.
Bühlmayer P; Criscione L; Fuhrer W; Furet P; de Gasparo M; Stutz S; Whitebread S
J Med Chem; 1991 Oct; 34(10):3105-14. PubMed ID: 1920360
[TBL] [Abstract][Full Text] [Related]
40. Preliminary biochemical characterization of two angiotensin II receptor subtypes.
Whitebread S; Mele M; Kamber B; de Gasparo M
Biochem Biophys Res Commun; 1989 Aug; 163(1):284-91. PubMed ID: 2775266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
